View on GitHub

The following assertions sourced from recent FDA approvals were added to the Molecular Oncology Almanac in this release -

Added entries:

  • (FDA) IDH1 p.R132C, p.R132H and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
  • (FDA) IDH1 somatic variants and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
  • (FDA) PDGFRA p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors.
  • (Preclinical) KIT p.D816V and sensitivity to avapritinib in gastrointestinal stromal tumors.
  • (Preclinical) KIT exon 11 and 17 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors.
  • (Preclinical) KIT somatic variants and sensitivity to avapritinib in mast cell leukemia.
  • (Preclinical) PDGFRA p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors.
  • (Preclinical) PDGFRA exon 18 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors

Revised entries:

  • (Guideline) PDGFRA p.842V and sensitivity to imatinib was revised to not sensitive.